Show simple item record

 
dc.contributorDepartament de Salut
dc.date.accessioned2018-11-15T13:46:18Z
dc.date.available2018-11-15T13:46:18Z
dc.date.issued2017-02-22
dc.identifier.citationOmalizumab, mepolizumab i reslizumab: indicació avaluada; tractament de l'asma greu no controlada en pacients adults. Barcelona: Servei Català de la Salut; 2017.
dc.identifier.urihttp://hdl.handle.net/11351/3659
dc.descriptionSevere asthma; Pharmacological treatment; Adult patients
dc.description.abstractAsthma is a chronic inflammatory disease of the respiratory tract, in which several cells and mediators of inflammation intervene, partly conditioned by genetic factors, which performs with bronchial hyperresponse (HRB) and a variable obstruction at Air flow, totally or partially reversible spontaneously or by medication action. It really is a very heterogeneous disease and is currently talking about a syndrome that groups several clinical phenotypes (clinical entities that share similar manifestations, but probably different etiologies) and endotips 6 (clinical entities that share molecular mechanisms of the disease ). The characterization of asthma includes two key concepts: the severity and control of the disease. The severity of asthma (intermittent, mild, moderate and severe) is determined based on the minimum maintenance maintenance requirements (maintenance steps) to achieve disease control. Control of asthma (well controlled, partially controlled and poorly controlled) is established based on the degree of control of the symptoms, exacerbations and pulmonary function:
dc.language.isocat
dc.publisherServei Català de la Salut
dc.relation.ispartofPrograma d'harmonització farmacoteràpeutica, Servei Català de la Salut
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAsma - Tractament
dc.subjectAparell respiratori - Malalties
dc.subjectMedicaments - Assaigs clínics
dc.subject.meshAsthma
dc.subject.mesh/drug therapy
dc.subject.meshDrug Evaluation
dc.titleOmalizumab, mepolizumab i reslizumab: indicació avaluada; tractament de l'asma greu no controlada en pacients adults
dc.typeinfo:eu-repo/semantics/report
dc.subject.decsasma
dc.subject.decs/tratamiento farmacológico
dc.subject.decsevaluación de medicamentos
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record